AbbVie (ABBV) Gross Margin (2012 - 2026)

AbbVie has disclosed Gross Margin across 15 years of filings, most recently posting 71.88% for Q1 2026.

• In Q1 2026, Gross Margin rose 188.0% year-over-year to 71.88%; the TTM figure through Mar 2026 stood at 70.68% (down 2.0% YoY), while the FY2025 annual figure was 70.24%, up 24.0% from the prior year.
• Gross Margin fell to 71.88% in Q1 2026, from 72.61% in the prior quarter.
• Over the last five years, Gross Margin for ABBV reached as high as 72.61% in Q4 2025 and fell as low as 53.44% in Q3 2023.
• The 5-year median for Gross Margin is 70.07% (2022), against an average of 68.38%.
• Annual changes were most pronounced in 2023 — Gross Margin sank 1266 bps — and 2024, when it soared 1744 bps.
• A 5-year view of Gross Margin shows it stood at 72.42% in 2022, then slipped by 17 bps to 60.11% in 2023, then increased by 18 bps to 70.89% in 2024, then gained by 2 bps to 72.61% in 2025, then dropped by 1 bps to 71.88% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 71.88%, 72.61%, and 66.38% for Q1 2026, Q4 2025, and Q3 2025 respectively.